Teva Pharmaceutical Industries Ltd traded at 9,176.00 this Thursday March 26th, decreasing 111.00 or 1.20 percent since the previous trading session. Looking back, over the last four weeks, Teva Pharmaceutical Industries lost 13.02 percent. Over the last 12 months, its price rose by 61.01 percent. Looking ahead, we forecast Teva Pharmaceutical Industries Ltd to be priced at 9,015.82 by the end of this quarter and at 8,248.87 in one year, according to Trading Economics global macro models projections and analysts expectations.
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.